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Purpose: To investigate whether combination treatment using an α-blocker and 2 mg of tolterodine could improve the International 
Prostate Symptom Score (IPSS) as much as α-blocker and 4 mg of tolterodine without voiding difficulties in real life practice.
Methods: We restrospectively recruited patients who were treated at four urology clinics between January 2006 and May 2008. A total 
of 1,094 men with lower urinary tract symptoms/overactive bladder (LUTS/OAB) were assigned to one of three groups: an α-blocker 
only group (group I, n=152), an α-blocker plus tolterodine 2 mg group (group II, n=520), and an α-blocker plus tolterodine 4 mg 
group (group III, n=574). Eligible patients were 50 years or older men who had a total IPSS of 8 or higher and a IPSS storage subscore 
of 5 or higher and were followed up for 12 weeks.
Results: The total IPSS score and quality of life scores were significantly improved at week 12 in groups II and III. The incidence of 
acute urinary retention was similar between both combination treatment groups, but the incidence of voiding difficulty was much 
lower in group II (2.1%) than group III (10.8%) tolterodine.
Conclusions: Our results suggest that treatment of LUTS/OAB patients with an α-blocker plus tolterodine 2 mg is as effective as 
α-blocker plus tolterodine 4 mg, and the incidence of voiding difficulty was in the low-dose anticholinergic is lower. These results 
indicate that dose strength should be decided on a case-by-case basis to balance the efficacy and safety.
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INTRODUCTION
Lower urinary tract symptoms (LUTS) and overactive blad-
der (OAB) are highly prevalent in the adult population, and 
the prevalence increases along with age [1,2]. OAB, which is 
defined by urgency, frequency, and nocturia, with or without 
incontinence, affects 15.6% of men aged 40 years and older in 
European countries [3]. Storage/OAB symptoms are bother-
some to patients, interfere with daily activities, and have a 
negative impact on patients’ quality of life (QoL) [4].
 Generally, women patients who complain of OAB are 
treated with anticholinergics as a first-line drug [5]. However, 
in male OAB patients, muscarinic receptor antagonists are 
not widely used because of the risk of urinary retention. 
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 Recently, several randomized trial have revealed that mus-
carinic receptor antagonists are effective and safe to be used 
in male OAB patients [6-8].
 Despite these reports, however, physicians have been reluc-
tant to use muscarinic receptor antagonists in real life practice, 
mainly because they often encounter patients who experi-
ence mild to moderate voiding difficulty after treatment with 
α-blockers and anticholinergics.
 Herein, we investigated whether combination treatment 
using an α-blocker and 2 mg of tolterodine improved the stor-
age subscore of the international prostate symptom score as 
much as a combination of α-blocker and 4 mg of tolterodine 
without voiding difficulty in men with LUTS/OAB symptoms 
in a clinical setting. 
MATERIALS AND METHODS
1. Patients
Patients were retrospectively recruited from those who were 
treated at four urology clinics in Korea between January 2006 
and May 2008. A total of 1,094 men with benign prostatic hy-
perplasia (BPH) and OAB were included in this study. 
 Eligible patients were men who were 50 years or older, 
had an International Prostate Symptom Score (IPSS) of 8 or 
higher and an IPSS storage subscore of 5 or higher, and were 
followed up for 12 weeks with the same drugs. 
 The exclusion criteria were as follows: men with clinically 
significant bladder outlet obstruction (BOO; defined as a post-
voided residual volume (PVR) >200 mL and a maximal uri-
nary flow rate <5 mL/sec), serum prostate-specific antigen 
(PSA) of more than 10 ng/mL with risk of prostate cancer, his-
tory of some neurologic condition affecting bladder function 
(e.g., multiple sclerosis, spinal cord injury, Parkinson’s dis-
ease), prostate cancer, prior surgery of the prostate or blad-
der, acute urinary retention (AUR) requiring catheterization, 
BOO due to causes other than BPH, history of treatment with 
a drug affecting voiding function such as an α-blocker within 
2 weeks, anticholinergics within 1 month, or a 5α reductase 
inhibitor within 3 months. Of patients who were prescribed 
tolterodine 2 mg at baseline, 141 patients were also excluded 
as the dose was increased to 4 mg during the 12-week period 
of treatment because of no improvement in storage symptoms. 
The Institutional Review Board of our institution approved 
this study.
2. Study design
All subjects were divided into three groups according to the 
physician’s preference: an α-blocker group (group I, n=152), 
an α-blocker plus tolterodine 2 mg group (group II, n=520), 
and an α-blocker plus tolterodine 4 mg group (group III, 
n=574). Four urologists treated their patients based on the 
personal preferences. When subjects experienced grade 3 ur-
gency (voiding cannot be delayed for more than 15 minutes, 
proposed by De Wachter and Wyndaele [9]) at least once a 
day through 3 days of voiding diary, we subscribed combi-
nation drugs (α-blocker plus tolterodine). Of these, subjects 
who had less than 100 mL of PVR were assigned to group III, 
subjects with greater than 100 mL of PVR in group II. The re-
maining subjects formed group I. 
 Serum PSA levels, maximal flow rate (Qmax) according to 
uroflowmetry (Urodyn 1000, Medtronics, Minneapolis, MN, 
USA) PVR (BladderScan BVI 3000, Verathon Inc., Bothell, WA, 
USA), and prostate volume (Pro Focus Ultra View type 2202, 
BK medical Aps, Peabody, MA, USA) at baseline were evalu-
ated in all patients. 
 Total IPSS score and QoL score were assessed at baseline 
and at week 12, and are reported as changes from baseline 
values. Patients were asked about adverse events at every 
visit, and all adverse events were recorded. Voiding difficulty 
was defined as an adverse event if the subject complained of 
new bladder emptying symptoms after 2 weeks of receiving 
the study medications.
3. Statistical analysis
Based on the characteristics of the data, mean±standard devi-
ations were calculated. The paired t-test was used to compare 
data before and after the 12-week treatment for each group. 
One-way analysis of variance was used to compare data among 
the three groups. When significance was detected, Scheffe’s 
test was used to ascertain intergroup significance. Values of 
P=0.05 were considered significant. 
RESULTS
Patients demographic and baseline clinical characteristics are 
summarized in Table 1. The mean subject age was 65.1 years 
old (range, 40 to 75 years). There were no significant differ-
ences in age, prostate volume, PSA levels, or the mean Qmax 
among the three groups.
 The total IPSS score, IPSS voiding & storage subscores, 
and QoL score were significantly improved at week 12 after 
therapy compared to baseline in all three groups (Fig. 1). 
IPSS subscores for storage symptom and urgency were only 
significantly improved in the combination therapy groups 
even though group III was more effective in terms of urgency 
compared to group II (Figs. 1, 2). However, there was no sig-
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nificant difference in the change in IPSS storage subscores 
and QoL between groups II and III (Fig. 2).
 Patients in the combination therapy groups experienced 
Fig. 1. Comparison of the efficacy of the three regimens. All subjects were assigned to one of three groups: an α-blocker group 
(group I), an α-blocker plus tolterodine 2 mg group (group II), and an α-blocker plus tolterodine 4 mg group (group III). All groups 
showed a significant difference in baseline scores and scores at 12 weeks. IPSS, International Prostate Symptom Score.
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Table 1. Subject characteristics of the α-blocker-only group 
and the two combination therapy groups
Characteristic α-blocker
α-blocker+ 
tolterodine 
SR 2 mg
α-blocker+ 
tolterodine 
SR 4 mg
P-value*
No. of patients 152 520 574  
Age (yr) 63±3.4 66±4.3 65±3.7 0.57
Prostate volumea) (g) 29.4±12.4 30.8±18.3 30.9±17.3 0.76
PSA (ng/mL) 1.89±1.3 1.88±0.7 1.92±1.0 0.19
Qmaxb) (mL/sec) 9.6±2.6 10.3±5.4 10.1±4.6 0.24
Total IPSS score 18.9±7.7 20.1±9.3 20.3±9.2 0.05
Voiding subscore 13.5±4.5 11.2± 5.1 11.0±5.2 0.12
Storage subscore 5.4±3.0 8.8±3.7 9.3±4.1 0.01
Q #1 frequency 1.9±1.3 3.4±1.3 3.6±1.3 0.03
Q #4 urgency 1.5±1.4 3.0±1.5 2.7±1.6 0.01
Q #7 nocturia 1.0±1.0 2.9±0.7 3.0±0.8 0.02
Quality of life 4.1±1.0 4.3±1.1 4.5±1.3 0.56
Values are presented as mean±standard deviation.
PSA, prostate-specific antigen; Qmax, maximal urine flow.
a)Measured by transrectal ultrasound. b)Measured by uroflowmetry. 
*P<0.05 among the three groups by analysis of variance, no statistical 
difference between the tolterodine 2 mg and 4 mg combination thera-
py groups.
symptoms such as dry mouth and voiding difficulty. More 
group III patients complained of adverse events than those in 
group II. However, the incidence of AUR was not significantly 
different among the three groups (Table 2).
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Fig. 2. Comparison of International Prostate Symptom Score 
(IPSS) scores on urgency according to treatment regimen. All 
subjects were assigned to one of three groups: an α-blocker 
group (group I), an α-blocker plus tolterodine 2 mg group 
(group II), and an α-blocker plus tolterodine 4 mg group (group 
III). Significant difference between baseline results and those 
measured at 12 weeks. There were no significant change in the 
urgency score between baseline and 12 weeks between groups 
II and III (P=0.09).
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DISCUSSION
The combination therapy with 2 mg of tolterodine and an 
α-blocker was effective and had a lower rate of adverse events 
than the one combining 4 mg tolterodine and an α-blocker. 
Therefore, the combination therapy with 2 mg of tolterodine 
is reasonable for patients with LUTS and mild to moderate 
voiding urgency. 
 Alpha1-adrenergic antagonists are widely used to treat LUTS 
because of their rapid effects and safety. In patients with 
LUTS accompanied by OAB, however, monotherapy with an 
α-blocker is not effective [10]. 
 Therefore, it would be logical to assume that adding an anti-
cholinergic would helpful for the management of these symp-
toms. However, anticholinergics decrease bladder contractility 
by blocking acetylcholine binding at muscarinic receptors in 
the bladder. These effects do not inhibit overactive detrusor 
contraction. However, they may theoretically exacerbate void-
ing symptoms, residual urine volume or, even worse, provoke 
AUR. 
 Abrams et al. [6] randomly treated 221 men with urody-
namically verified (BOO) with oral tolterodine 2 mg for 12 
weeks. Changes from baseline urodynamics in the patients 
treated with tolterodine were statistically equivalent to those 
who received a placebo. The median increase in PVR was 
significantly greater in the tolerodine group (25 mL) than the 
placebo group (0 mL). AUR was reported in one patient in 
each group. 
 Kaplan et al. [11] treated 39 men who did not respond to 
α-blocker therapy for 5.7 months with tolterodine 4 mg mono-
therapy for 6 months. They concluded that monotherapy with 
4 mg of tolterodine induced a significant increase in the Qmax 
of patients and decreased PVR, in contrast to the results re-
ported by Abrams et al. [6].
 These contradicting safety findings indicate that large, 
placebo-controlled studies in men with OAB symptoms and 
other LUTS are needed to confirm the efficacy and safety of 
anticholinergics. 
 In a meta-analysis of randomized controlled trials which 
used anticholinergics to treat OAB, most anticholinergics 
were safe and effective except oxybutynin which significantly 
increased the risk of AUR compared with placebo [12].
 Despite the evidence that anticholinergics can safely and 
effectively treat OAB symptoms in men, only 40% of men 
with OAB symptoms who received drug treatment were pre-
scribed anticholinergics [13]. Recent studies suggest that a 
combination of antimuscarinic and α1-receptor antagonist 
may more effectively reduce male LUTS than the use of α1-
receptor antagonists alone. 
 Athanasopoulos et al. [8] used a combination of tamsulosin 
0.2 mg and tolterodine 2 mg to treat 50 patients with BOO and 
detrusor overactivity, and reported improvement in QoL and 
bladder volume. Furthermore, no AUR occurred in any of the 
patients.
 A few randomized controlled trials have demonstrated 
that anticholinergics are a safe option in patients with mild to 
moderate risk of BOO [7,14,15].
 However, previous studies of the safety of medications fo-
cused on the rate of urinary retention or increased residual 
volume rather than voiding difficulty as a subjective symptom 
after treatment. Based on our clinical experience, however, 
patients who take anticholinergics may complain of voiding 
difficulty without urinary retention or increased residual 
volume. In this study, only 5 subjects who were treated with 
combination therapies complained of AUR during the study 
period. However, 14.6 times more subjects (n=73) com-
plained of voiding difficulty in combination therapy groups. 
These showed the high prevalence of voiding difficulty com-
pared to previous studies [7,14,15]. This could be attributed to 
the fact that we included mild to moderate symptoms of void-
ing difficulty. Actually, AUR frequently occurs in subjects with 
severe voiding difficulty. Although it may not be considered 
as a serious issue to many other investigators, we believe that 
subjective symptoms should not be neglected.
 Because we think previous studies did not well reflect real 
life practice in respect of safety of regimen, in this study, we 
investigated the optimal combination dose of anticholiner-
gics and α-blocker to minimize urinary or nonurinary side 
effects and maintain the efficacy of the combination therapy. 
We found that 2 mg of tolterodine and an α-blocker regimen 
was effective in patients with OAB and resulted in much less 
voiding difficulty and dry mouth symptoms than combina-
tion therapy with tolterodine 4 mg Therefore, we suggest that 
a combination therapy of an α-blocker and tolterodine 2 mg 
is a feasible regimen in male patients with mild-to-moderate 
Table 2. No. of patients that experienced adverse events ac-
cording to treatment group
No. of 
α-blocker 
No. of α-blocker+ 
tolterodine  
SR 2 mg
No. of α-blocker+ 
tolterodine  
SR 4 mg
Dizziness 3 (0.2) 4 (0.7) 6 (1.8)
Dry mouth 0 (0) 13 (2.5) 52 (9.0)
Voiding difficulty 0 (0) 11 (2.1) 62 (10.8)
AUR 1 (0.6) 2 (0.3) 3 (0.5)
Values are presented as number (%). 
AUR, acute urinary retention.
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OAB and patients who present severe storage symptoms and 
want to minimize dry mouth symptom and voiding difficulty. 
 There were some limitations in this study. First, our analy-
sis was based on the results of an open-label, retrospective, 
observational study without a placebo control, which limits 
interpretation of the data. However, the study included a large 
number of subjects, which allowed analysis of multiple sub-
groups. Furthermore, as patients were treated and data were 
recorded under real-life conditions, the findings are likely to 
be applicable in clinical practice.
 A second limitation of this study was that the follow-up pe-
riod was relatively short compared to other studies. However, 
we believe that a period of 12 weeks is reasonable to evaluate 
the efficacy and safety of a drug regimen. 
 In conclusion, our results suggest that treatment of LUTS/
OAB patients with an α-blocker plus tolterodine 2 mg resulted 
in less side effects and was as effective as treatment of LUTS/
OAB patients with an α-blocker and tolterodine 4 mg. How-
ever, the combination of tolterodine 4 mg with an α-blocker 
resulted in greater improvement in urgency symptoms than 
other regimens evaluated in this study. Therefore, we suggest 
that the combination therapy for the treatment of LUTS/OAB 
be customized each patient. 
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